enGene Therapeutics Inc.
ENGNW·NasdaqCM
0.2299+0.0400 (+21.06%)today
At close: Oct 23, 1:14 PM EDT · May be delayed up to 15 min · USD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close0.1899
Open2.1000
Day range0.20000.2399
52-week range0.20000.2399
Off day high−4.17%
Off 52-week high−4.17%
Volume2.66K
Avg. volume (3M)—
Market cap—
EPS (TTM)—
Forward P/E—
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)-0.29
Shares outstanding—
Short interest—
Earnings date—
Analyst target—
Profit margin0.00%
Against its peers
Compare in full ›| ENGNW | CADL | URGN | ELVN | XBIO | BIIB | |
|---|---|---|---|---|---|---|
| Market cap | — | 614.44M | 1.69B | 3.04B | 4.03M | 37.04B |
| P/E (TTM) | — | — | — | — | — | 44.5 |
| Forward P/E | — | -12.8 | 13.3 | -17.9 | -2.6 | 15.2 |
| Price/book | 0.1 | 4.8 | -12.7 | 3.4 | 0.7 | 2.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | — | +55.19% | +85.29% | +103.44% | −51.87% | +69.35% |
| Today | +21.06% | −4.18% | −1.88% | −0.98% | −10.88% | −1.24% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All ENGNW news ›enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment - Slideshow
2026-10-19. The following slide deck was published by enGene Therapeutics Inc. The following slide deck was published by enGene Therapeutics Inc. in conjunction with this event.
From articles in the 4Search news index.